Research at the BBZ  

Research at the BBZ

Target Agreement

With the completion of the target agreement for the Centre for Biotechnology and Biomedicine between the State Ministry for Science and the Arts of Saxony and the Leipzig University for the period from 2007 to 2013, the specified infrastructural development continued with the research and development program "THERANOSTIK – Therapie und Diagnostik der Zukunft mit Spezialisierung, Visualisierung und Miniaturisierung: Wirkstoffe und Zellen als Produkte und Instrumente" ["Future Therapies and Diagnostics with Specialization, Visualization and Miniaturization: Active Substances and Cells as Products and Instruments"] for the sustainable continuation of the biotechnology initiative in the Free State of Saxony.

To implement the research program, university-wide innovative and collaborative joint projects are being funded in four subject areas.

Subject Areas of Target Agreement

Subject Area 1
Research, development and validation of tools and technologies for high-throughput screening and diagnostics and rational agent discovery

  • Integrative pharmacogenomic applications in the treatment of cardiovascular, neurodegenerative, oncological, endocrine/metabolic diseases
  • Development of new, intelligent nano-/microstructure-cell-/membrane interfaces for use in diagnostics and therapy
  • Development of systems biology approaches for the development of in silico cell, tissue and molecular models – new predictive systems for diagnostics, therapy and active substance testing
  • Development of bioactive, intelligent (micro)implants and cell transplants for the reparation, regeneration and control of biological processes
  • Genetic reprogramming of cells, cell lines and stem cells for the treatment of inherited or acquired diseases

Subject Area 2
Exploration of molecular causes and development of strategies for the treatment of infectious and neurodegenerative diseases, in particular Alzheimer's disease

In the field of infectious diseases, new drugs will be developed and validated as well as new target proteins identified. In the field of neurological diseases, new diagnostic and therapeutic strategies based on promising molecular target structures should be pursued.

last update: 07.09.2016 


Centre for Biotechnology and Biomedicine
Deutscher Platz 5
04103 Leipzig

Phone: +49 341 97-31300
Fax: +49 341 97-31309

Prof. Dr. Andrea A. Robitzki

Chief Executive Officer
Dr. Svenne Eichler